In vivo studies using mouse models have demonstrated that PARP inhibitors are effective against IDH mutant myeloproferative syndrome (MDS)/AML and can overcome resistance to targeted IDH inhibitors [152]. Here, IDH1 is linked to acute myeloid leukemia.